Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Reinhardt

Showing results (191-200 of 236) with videos related to

Pageof 24
Sort By:
Journal of Hematology & Oncology|May 21, 2026
Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysisNico Gagelmann, Hermann Einsele, Sarah Flossdorf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2019
EZH2 Is Overexpressed in <i>BRCA1</i>-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based ChemotherapyJulian Puppe, Mark Opdam, Philip C Schouten, et al.
Leukemia|May 8, 2023
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysisPhilipp Berning, Norbert Schmitz, Maud Ngoya, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 19, 2023
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapyConrad-Amadeus Voltin, Andrea Paccagnella, Michael Winkelmann, et al.
Blood|March 28, 2022
Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignanciesElena Izquierdo, Daniela Vorholt, Stuart Blakemore, et al.
The EMBO Journal|August 23, 2012
AATF/Che-1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosisKatja Höpker, Henning Hagmann, Safiya Khurshid, et al.
Leukemia|July 1, 2026
Feasibility and safety of rapid glofitamab ramp-upCeline H Liem, Rebecca Wurm-Kuczera, David Böckle, et al.
American Journal of Hematology|February 15, 2024
Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysisNico Gagelmann, Gabriela S Hobbs, Edoardo Campodonico, et al.
Nature Cancer|August 14, 2023
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaRenáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
Cancer Cell|August 22, 2025
Lymphoma accelerates T cell and tissue agingRebecca S Hesterberg, Joshua T Davis, Komal J Handoo, et al.
Pageof 24

Showing results (191-200 of 236) with videos related to

Sort By:
Pageof 24
Journal of Hematology & Oncology|May 21, 2026
Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysisNico Gagelmann, Hermann Einsele, Sarah Flossdorf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2019
EZH2 Is Overexpressed in <i>BRCA1</i>-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based ChemotherapyJulian Puppe, Mark Opdam, Philip C Schouten, et al.
Leukemia|May 8, 2023
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysisPhilipp Berning, Norbert Schmitz, Maud Ngoya, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 19, 2023
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapyConrad-Amadeus Voltin, Andrea Paccagnella, Michael Winkelmann, et al.
Blood|March 28, 2022
Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignanciesElena Izquierdo, Daniela Vorholt, Stuart Blakemore, et al.
The EMBO Journal|August 23, 2012
AATF/Che-1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosisKatja Höpker, Henning Hagmann, Safiya Khurshid, et al.
Leukemia|July 1, 2026
Feasibility and safety of rapid glofitamab ramp-upCeline H Liem, Rebecca Wurm-Kuczera, David Böckle, et al.
American Journal of Hematology|February 15, 2024
Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysisNico Gagelmann, Gabriela S Hobbs, Edoardo Campodonico, et al.
Nature Cancer|August 14, 2023
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaRenáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
Cancer Cell|August 22, 2025
Lymphoma accelerates T cell and tissue agingRebecca S Hesterberg, Joshua T Davis, Komal J Handoo, et al.
Pageof 24